Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity.
Autor: | Baiocchi GC; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Vojdani A; Immunosciences Laboratory, Inc., Department of Immunology, Los Angeles, California, USA.; Cyrex Laboratories, Phoenix, Arizona, USA., Rosenberg AZ; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Vojdani E; Regenera Medical, Los Angeles, California, USA., Halpert G; Ariel University, Ariel, Israel.; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Saint Petersburg State University Russia, St Petersburg, Russia., Ostrinski Y; Ariel University, Ariel, Israel.; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Saint Petersburg State University Russia, St Petersburg, Russia., Zyskind I; Department of Pediatrics, NYU Langone Medical Center, New York, New York, USA.; Maimonides Medical Center, Brooklyn, New York, USA., Filgueiras IS; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Schimke LF; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Marques AHC; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Giil LM; Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway., Lavi YB; Department of Chemistry Ben Gurion University Beer-Sheva, Beer-Sheva, Israel., Silverberg JI; Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, USA., Zimmerman J; Maimonides Medical Center, Brooklyn, New York, USA., Hill DA; ResourcePath, Sterling, Virginia, USA., Thornton A; ResourcePath, Sterling, Virginia, USA., Kim M; Data Science Initiative at Brown University, Providence, Rhode Island, USA., De Vito R; Department of Biostatistics and the Data Science Initiative at Brown University, Providence, Rhode Island, USA., Fonseca DLM; Interunit Postgraduate Program on Bioinformatics, Institute of Mathematics and Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil., Plaça DR; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, São Paulo, Brazil., Freire PP; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Camara NOS; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Calich VLG; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Scheibenbogen C; Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Heidecke H; CellTrend Gesellschaft mit beschränkter Haftung (GmbH), Luckenwalde, Germany., Lattin MT; Department of Biology, Yeshiva University, Manhatten, New York, USA., Ochs HD; Department of Pediatrics, University of Washington School of Medicine, and Seattle Children's Research Institute, Seattle, Washington, USA., Riemekasten G; Department of Rheumatology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany., Amital H; Ariel University, Ariel, Israel.; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Shoenfeld Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.; Saint Petersburg State University Russia, St Petersburg, Russia., Cabral-Marques O; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.; Interunit Postgraduate Program on Bioinformatics, Institute of Mathematics and Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil.; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, São Paulo, Brazil.; Department of Pharmacy and Postgraduate Program of Health and Science, Federal University of Rio Grande do Norte, Natal, Brazil.; Department of Medicine, Division of Molecular Medicine, University of São Paulo School of Medicine, Baltimore, USA.; Laboratory of Medical Investigation 29, University of São Paulo School of Medicine, São Paulo, Brazil. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of medical virology [J Med Virol] 2023 Feb; Vol. 95 (2), pp. e28538. |
DOI: | 10.1002/jmv.28538 |
Abstrakt: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with increased levels of autoantibodies targeting immunological proteins such as cytokines and chemokines. Reports further indicate that COVID-19 patients may develop a broad spectrum of autoimmune diseases due to reasons not fully understood. Even so, the landscape of autoantibodies induced by SARS-CoV-2 infection remains uncharted territory. To gain more insight, we carried out a comprehensive assessment of autoantibodies known to be linked to diverse autoimmune diseases observed in COVID-19 patients in a cohort of 231 individuals, of which 161 were COVID-19 patients (72 with mild, 61 moderate, and 28 with severe disease) and 70 were healthy controls. Dysregulated IgG and IgA autoantibody signatures, characterized mainly by elevated concentrations, occurred predominantly in patients with moderate or severe COVID-19 infection. Autoantibody levels often accompanied anti-SARS-CoV-2 antibody concentrations while stratifying COVID-19 severity as indicated by random forest and principal component analyses. Furthermore, while young versus elderly COVID-19 patients showed only slight differences in autoantibody levels, elderly patients with severe disease presented higher IgG autoantibody concentrations than young individuals with severe COVID-19. This work maps the intersection of COVID-19 and autoimmunity by demonstrating the dysregulation of multiple autoantibodies triggered during SARS-CoV-2 infection. Thus, this cross-sectional study suggests that SARS-CoV-2 infection induces autoantibody signatures associated with COVID-19 severity and several autoantibodies that can be used as biomarkers of COVID-19 severity, indicating autoantibodies as potential therapeutical targets for these patients. (© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.) |
Databáze: | MEDLINE |
Externí odkaz: |